Pulmonary arterial hypertension (PAH) is a severe cardiopulmonary disease characterized by elevated pulmonary artery pressure and cardiac dysfunction, often leading to heart failure and even death.
Given the heterogeneity of the tumor microenvironment (TME), neoadjuvant immunotherapy combined with chemotherapy benefits only a subset of lung adenocarcinoma (LUAD) patients, and the mechanisms of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results